Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Chemomab Therapeutics Ltd. - American Depositary Shares
(NQ:
CMMB
)
1.690
-0.110 (-6.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Chemomab Therapeutics Ltd. - American Depositary Shares
< Previous
1
2
3
4
5
6
Next >
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
December 02, 2025
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
November 24, 2025
From
Chemomab Therapeutics Ltd.
Via
GlobeNewswire
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 20, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
November 06, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
August 21, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 19, 2025
Via
Benzinga
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
August 14, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
June 30, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
June 11, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
June 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 15, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
May 05, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
April 28, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
April 21, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Announces New Medical and Clinical Appointments
April 15, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease
↗
March 27, 2025
Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.
Via
Benzinga
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
March 27, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
March 25, 2025
Via
Benzinga
New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
March 06, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
March 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
February 19, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
December 03, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
November 19, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 14, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
October 30, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
October 15, 2024
Via
Benzinga
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
October 15, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
Chemomab Therapeutics to Present at October 2024 Investor Conferences
October 01, 2024
From
Chemomab Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
